HeartBeam (BEAT)
NASDAQ:BEAT
Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$48.77M
Enterprise Value$28.22M
Total Cash (Recent Filing)$2.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 06, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding55,506,836
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.18K
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$3.90Price Target Upside52.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$1.83M
Bulls Say, Bears Say
Bulls Say
Extended Liquidity RunwayThe $11.5M underwritten offering lifting pro forma cash to ~$12.4M materially reduces near-term financing pressure, giving management capital to complete pilots, advance regulatory work, and support early commercial rollouts. This improves short- to mid-term execution optionality and de-risks immediate funding needs.
Regulatory Foundation (FDA Clearances)Two FDA clearances for arrhythmia assessment establish a regulatory and commercial foothold, enabling limited launches and payer/clinic engagement. This regulatory precedent lowers incremental approval risk for adjacent indications and supports durable market access strategies versus peers without clearance.
Product & Clinical De-risking With Strategic CollaborationA Mount Sinai AI collaboration, a working 12-lead patch prototype, and enrollment momentum in ALIGN‑ACS demonstrate tangible product progress and clinical validation. Combined, these increase the likelihood of differentiated algorithms and clinical acceptance, strengthening long-term competitive positioning.
Bears Say
Pre‑Revenue With Large Net LossesHeartBeam remains pre-revenue while incurring substantial net losses (~$13M–$21M annually). Without meaningful commercial receipts yet, the business lacks self-sustaining cash generation, extending reliance on external capital and lengthening the timeline to profitability and intrinsic value creation.
Negative Cash Flow And Shrinking EquityPersistently negative operating and free cash flow, coupled with equity declining from ~$15.9M (2023) to ~$0.6M TTM, indicate the company is burning capital and exhausting its balance sheet cushion. Even with recent financing, ongoing cash consumption elevates refinancing and dilution risk over the next 6–12 months.
Commercial & Regulatory Execution RiskPatch commercialization depends on partnership deals not yet secured, and MI indication timing is uncertain. A lean early sales model further slows scale. These structural adoption and go-to-market risks could delay revenue realization and widen the gap between clinical progress and sustainable commercial traction.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $48.77M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Aug 06, 2026 which is in 72 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.015.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.09.
How many shares outstanding does HeartBeam have?
HeartBeam has 55,506,836 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went up 2.97%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.90 (52.34% Upside)
$3.90 (52.34% Upside)
Insider Transactions
Bought Shares
Worth $905.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-1034.04%
Trailing 12-Months
Asset Growth
-56.86%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress across multiple fronts — financing closed to extend runway, prototype completion and pilot initiations for the 12‑lead patch, enrollment momentum in ALIGN‑ACS, strategic Mount Sinai AI collaboration, and initial commercial anchor partnerships in four target geographies. At the same time, the company remains an early‑stage commercial operation with a Q1 net loss of $4.7M, limited near‑term revenue, reliance on future studies and regulatory approvals for MI indication, and continued cash consumption (though operating cash burn improved 19% YoY and full‑year outflow guidance was reduced to under $16M). On balance, the highlights (funding, clinical progress, partnerships, prototype, AI collaboration, reduced burn) outweigh the lowlights (losses, limited revenue, regulatory and adoption risk), yielding a cautiously positive outlook as the company advances toward de‑risking key milestones.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$3.90
▲(52.34% Upside)
Technical Analysis
Ownership Overview
10.47% Insiders
2.11% Mutual Funds
1.69% Other Institutional Investors
83.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---